The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.Linvention concerne la combinaison pharmaceutique dun anticorps anti-CD38 et de lénalidomide, et la combinaison pharmaceutique dun anticorps anti-CD38 et de bortézomib.